Clozapine versus other atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Asenjo, Claudia A ^a   Komossa, K ^b   Leucht, S ^b   Hunger, H ^b   Rummel, C ^b   Schmidt, F ^b   Schwarz, S ^b  

^a UNIVERSITY OF HOHENHEIM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

CLINICAL PROTOCOL; CLINICAL RESEARCH; COCHRANE LIBRARY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; REVIEW; SCHIZOPHRENIA;

EID: 44949089668     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006633     Document Type: Review

References (35)

1. ACP 2002 William T. Carpenter, M.D, K. Thaker, M.D. Schizophrenia: Management. ACP Medicine online 2002; Vol. Section 13 Psychiatry, issue VII. Schizophrenia.
2. Altman 1996 Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200.
3. Beaumont 2000 George Beaumont. Antipsychotics - The Future of Schizophrenia Treatment. Curr Med Res Opin 2000;16(1):37-42.
4. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
5. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problemof therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
6. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-690.
7. Citrome 2002 Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. Journal of psychiatric practice 2002;8(4):205-215. [MEDLINE: 15985880].
8. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
9. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
10. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
11. Furukawa 2006 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
12. Gaebel 1997 Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. International Clinical Psychopharmacology 1997;12 Suppl 1:S37-S42. [MEDLINE: 228].
13. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
14. Heres 2006 Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185-94.
15. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
16. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. The Cochrane Library 2005, issue 3.
17. Idänpään- He.1977 Idänpään- Heikkilä J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. European Journal of Clinical Pharmacology 1977;11(3):193-198.
18. Kane 1988 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45(9):789-796. [MEDLINE: 3046553].
19. Kane 1990 Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica Suppl 1990;358:151-7.. [MEDLINE: 1978476].
20. Kane 2006 Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology 2006;21(1):21-28. [MEDLINE: 230].
21. Kay 1986 Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
22. Leucht 2005a Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
23. Leucht 2005b Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
24. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
25. McEvoy 2006 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10.. [MEDLINE: 16585434].
26. Miyamoto 2005 Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005;10(1):79-104. [MEDLINE: 182].
27. Naheed 2001 Naheed M, Green B. Focus on clozapine. Curr Med Res Opin 2001;17(3):223-9. [MEDLINE: 11900316].
28. O'Brien 2004 O'Brien A. Starting clozapine in the community: a UK perspective. CNS Drugs 2004;18(13):845-52. [MEDLINE: 15521789].
29. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
30. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
31. Stroup 2003 Stroup S, McEvoy J, Swartz MS, Byerly M, Glick I, Canive J, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. Schizophrenia Bulletin 2003;29(1):15-31.
32. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317].
33. Wahlbeck 1999 Wahlbeck K, Cheine MV, Essali A. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 4.Art. No.: CD000059. DOI: 10.1002/14651858.CD000059.
34. Tuunainen 1999 Tuunainen A, Gilbody S. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 1999, Issue 1.Art. No.: CD000966. DOI:10.1002/14651858.CD000966.
35. Tuunainen 2000 Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 2.Art. No.: CD000966. DOI:10.1002/14651858.CD000966.[MEDLINE: DOI: 10.1002/14651858].